An Expanded Access Program in China to Provide Spesolimab to People With a Flare-up in Generalized Pustular Psoriasis Who Have no Other Treatment Options

PHASE3CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

March 15, 2022

Primary Completion Date

July 17, 2023

Study Completion Date

July 17, 2023

Conditions
Generalized Pustular Psoriasis
Interventions
DRUG

spesolimab

spesolimab

Trial Locations (12)

30052

Tianjin Medical University General Hospital, Tianjin

100050

Beijing Friendship Hospital, Beijing

110001

The First Hospital of China Medical University, Shenyang

200000

Shanghai Skin Disease Hospital, Shanghai

210000

Dermatology Hospital, Chinese Academy of Medical Sciences, Nanjing

250063

Shandong Provincial Hospital of Dermatology, Jinan

310009

The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou

310013

Hangzhou Third People's Hospital, Hangzhou

430022

Wuhan Union Hospital, Wuhan

510091

Southern Medical University Dermatology Hospital, Guangzhou

518053

The University of Hong Kong-Shenzhen Hospital, Shenzhen

610041

West China Hospital, Chengdu

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT05239039 - An Expanded Access Program in China to Provide Spesolimab to People With a Flare-up in Generalized Pustular Psoriasis Who Have no Other Treatment Options | Biotech Hunter | Biotech Hunter